Actively Recruiting
MicroRNA-371 as Markers for Disease Activity and Monitoring Chemotherapy and Recurrence in Testicular Germ Cell Tumors
Led by Haukeland University Hospital · Updated on 2022-08-08
350
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
Sponsors
H
Haukeland University Hospital
Lead Sponsor
K
Karolinska University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the use of microRNA-371a-5p (miR371) as a marker to manage testicular germ cell cancer. The study aims to determine how well miR371 detects active tumor cells during orchiectomy, treatment, surveillance, and in the early detection of cancer recurrence. This observational study focuses on improving monitoring methods for patients with different stages of testicular cancer. Participants will have blood samples collected at diagnosis, during treatment, during surveillance, and every 3 to 6 months to analyze miR371 levels. The study tracks the biomarker's performance at key points such as orchiectomy, retroperitoneal lymph node dissection (RPLND), chemotherapy, and recurrence detection over a 5-year period. During the study, participants will undergo regular blood draws to monitor miR371 as a biomarker. Researchers will assess how well miR371 corresponds to disease activity and treatment effects. The study provides long-term follow-up to observe biomarker changes and detect possible recurrence, helping guide future care strategies for testicular germ cell cancer patients.
CONDITIONS
Brief Title
MicroRNA as Markers in Testicular Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspected testicular cancer referred to orchiectomy
- Patients diagnosed with testicular germ cell cancer
- Age 18 to 70 years
- Able to receive information and provide consent
You will not qualify if you...
- History of other prior or current cancers besides testicular cancer
- Any disease or condition that prevents receiving information or participating in follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At diagnosis
Blood samples are collected at diagnosis to assess the presence of microRNA-371a-5p (miR371) as a biomarker for testicular germ cell tumors.
1 visit (in-person)
Duration - During chemotherapy treatment
Blood samples are collected during chemotherapy treatment to monitor miR371 levels and disease activity.
Visits as per treatment schedule
Duration - Up to 5 years
Participants are monitored through blood sample collection every 3 to 6 months to detect recurrence and assess disease activity post-treatment.
Blood collection every 3 to 6 months
Trial Site Locations
Total: 6 locations
1
Haukeland University Hospital
Bergen, Norway, 5021
Actively Recruiting
2
Haugesund Hospital
Haugesund, Norway, 5528
Actively Recruiting
3
Oslo University Hospital
Oslo, Norway, 0379
Not Yet Recruiting
4
University Hospital of North Norway
Tromsø, Norway, 9038
Actively Recruiting
5
Sahlgrenska University Hospital
Gothenburg, Sweden, 41345
Not Yet Recruiting
6
Karolinska University Hospital
Stockholm, Sweden
Actively Recruiting
Research Team
M
Mette Pernille Myklebust, PhD
O
Olav Dahl, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here